An interventional study of Zihninde Çok Kuran İnsanlar için Salma Rehberi and Çapa Atmak in Anxiety, Depression and Stress (Psychology), sponsored by Istanbul Nisantasi University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Istanbul Nisantasi University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 343 studies in Depression with a site in Turkey — 59 open to participants now, 71 under way, none of them phase 3. Depression · Turkey.
Among the 343 studies in Depression with a site in Turkey, this one is the 27th largest by planned enrollment of the 246 interventional ones that give a count, is one of 40 that started in 2026, is one of 239 with no phase, reaches primary completion later than 56 of the 70 other live ones, and was the 304th registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →59 of the 343 studies in Depression with a site in Turkey are open now. Recruiting first, the newest first:
Istanbul Physical Medicine Rehabilitation Training and Research Hospital · Sites in Turkey
Ages 18–65
Istanbul University · Sites in Turkey
Ages 18+
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 40–54 · Women only · Healthy volunteers
Hitit University · Sites in Turkey
Ages 50+ · Men only
Selcuk University · Sites in Turkey
Ages 18+ · Women only
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
343 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 40 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 165 is above the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 60 across the 246 interventional studies, 107 across the 97 observational. Of the 258 that completed or were terminated, 6 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 343 have an industry lead sponsor. The 10 most frequent:
Istanbul Nisantasi University is the lead sponsor of 22 studies on the registry; 8 are open to participants now.
Istanbul Nisantasi University has 3 studies filed under Depression — fewer than ten, so there is no comparison to draw.
24 of the studies in Depression with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07846410Istanbul Physical Medicine Rehabilitation Training and Research HospitalVirtual Reality-Based Hypnotherapy for Pain, Sleep, and Mood in Spinal Cord Injury | 2026-11 |
| NCT07444697Kırıkkale University"Erectile Function After PCI in MI and Non-MI Patients" | 2026-11 |
| NCT07517549Ordu UniversitySexual Health Education During Pregnancy | 2026-11-30 |
| NCT07718399Halic UniversitySpirulina Supplementation in Postmenopausal Women | 2026-12 |
| NCT07603804Istanbul University - CerrahpasaAccelerated iTBS for Major Depression | 2026-12 |
Add all 24 to your calendar (.ics) → With an account.
Among the 343 studies in Depression with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study tests whether reading a structured self-help book (bibliotherapy) can reduce anxiety, depression and stress and change unhelpful thinking patterns in medical and health-sciences students.
Students in health programs face heavy academic and clinical demands and are at increased risk of emotional distress. A thinking style called the Cognitive Attentional Syndrome (worry, rumination, threat monitoring and unhelpful coping) is thought to link stress to anxiety and depression. Metacognitive therapy targets this thinking style, and low-intensity self-help books may make these principles accessible to students.
A total of 165 students at İstanbul Nişantaşı University will be randomly assigned to one of three groups: two groups each receive a different self-help book and read it at their own pace over 8 weeks, and the third group (waitlist) receives the books after the study ends. All participants complete short online questionnaires (DASS-21, CAS-1, MCQ-30) at the start, at week 4 and at week 8, and receive brief telephone calls at weeks 2, 4 and 6 to confirm participation.
Design: Single-site, parallel-group, three-arm randomized controlled trial at İstanbul Nişantaşı University, Istanbul, Türkiye.
Participants: Students aged 18 years or older enrolled in medicine or health-sciences programs (medicine, psychology, nursing and dentistry), recruited through announcements (student WhatsApp groups, e-mail and brief in-class presentations). Participation is voluntary and has no effect on academic standing.
Arms: (1) Bibliotherapy with the self-help book "Zihninde Çok Kuran İnsanlar için Salma Rehberi"; (2) bibliotherapy with the self-help book "Çapa Atmak"; (3) waitlist control, assessment only during the study period, with books provided at the end of the study. Reading is self-paced over 8 weeks without therapist contact.
Randomization: After completion of baseline assessments, participants are allocated 1:1:1 using a computer-generated random sequence (Randomizer.org). Faculty and baseline DASS-21 total score are taken into account to support balance between groups; the DASS-21 score is not used as an inclusion threshold. The allocation list is stored securely by the research team, and allocation is not disclosed until baseline assessments are complete.
Sample size: G*Power 3.1, medium effect size (f = 0.25), three groups, α = 0.05, power 80%: minimum 159 participants. 165 participants (55 per arm) are targeted.
Measures and schedule: Sociodemographic form at baseline. Depression Anxiety Stress Scales-21 (DASS-21), Cognitive Attentional Syndrome Scale-1 (CAS-1) and Metacognitions Questionnaire-30 (MCQ-30) at week 0, week 4 and week 8, collected online through a study website after electronic informed consent. Process measures: a weekly one-item reading log in the two bibliotherapy arms, and a three-item contamination form at week 8.
Telephone contact: All participants, including the waitlist group, receive brief standardized telephone calls at weeks 2, 4 and 6 to confirm participation, reading progress and completion of forms. Calls follow a fixed script, serve reminder and confirmation purposes only, and contain no therapeutic content or guidance about the books, so that contact intensity is equal across arms.
Safety: Participants with current psychiatric treatment, a recent change in psychotropic medication, bipolar disorder, acute psychotic symptoms or suicide risk are not included. If questionnaire responses indicate a high level of distress during the study, the research team contacts the participant and refers them to appropriate mental health services.
Analysis: Repeated-measures ANOVA (or non-parametric alternatives) to examine group × time effects, with baseline scores taken into account; partial eta-squared is reported as the effect size; intention-to-treat principles are applied for missing data. SPSS is used.
Data protection: Participants are identified only by study codes. Telephone numbers are collected with consent for study contact only and stored separately from the dataset. Data are stored under encryption in accordance with Turkish personal data protection law (KVKK), and no personal identifiers appear in reports or publications.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
This study's planned enrollment of 165 is above the median of 81 across 7,089 interventional studies indexed under Depression.
Browse Depression studies →Istanbul Nisantasi University is the lead sponsor of 22 studies on the registry; 8 are open to participants now.
Compared within Depression, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The criteria were revised on the registry on Nov 2, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive the self-help book "Zihninde Çok Kuran İnsanlar için Salma Rehberi" at study start and read it at their own pace over 8 weeks. They complete online questionnaires at weeks 0, 4 and 8, a weekly one-item reading log, and receive brief telephone calls at weeks 2, 4 and 6.
Behavioral: Zihninde Çok Kuran İnsanlar için Salma Rehberi
Participants complete the same online questionnaires at weeks 0, 4 and 8 and receive the same brief telephone calls at weeks 2, 4 and 6. The study books are provided after the 8-week study period.
Participants receive the self-help book "Çapa Atmak" at study start and read it at their own pace over 8 weeks. They complete online questionnaires at weeks 0, 4 and 8, a weekly one-item reading log, and receive brief telephone calls at weeks 2, 4 and 6.
Behavioral: Çapa Atmak
Structured self-help book based on metacognitive therapy principles, targeting the Cognitive Attentional Syndrome (worry, rumination, threat monitoring and unhelpful coping strategies). Participants read the book at their own pace over 8 weeks without therapist contact. Reading progress is recorded with a weekly one-item online reading log.
Self-help book read under the same conditions as Intervention 1: self-paced reading over 8 weeks without therapist contact, with a weekly one-item online reading log.
Change in Depression, Anxiety, and Stress Scales (DASS-21) total score
DASS-21 (Turkish version), 21 items rated 0-3; total score is the sum of all items (range 0-63). Higher scores indicate greater psychological distress. Change from baseline to week 8 is compared between groups.
Time frame: Baseline (week 0) to week 8
Change in Cognitive Attentional Syndrome Scale-1 (CAS-1) score
CAS-1 (Turkish version), 16 items. Items 1-10 (worry/rumination, threat monitoring and unhelpful coping behaviours) are rated on a 0-8 scale; items 11-16 (metacognitive beliefs) are rated on a 0-100 scale. Higher scores indicate greater Cognitive Attentional Syndrome activity.
Time frame: Baseline (week 0), week 4 and week 8
Change in Metacognitions Questionnaire-30 (MCQ-30) total score
MCQ-30 (Turkish version), 30 items rated 1-4 (range 30-120). Higher scores indicate more maladaptive metacognitive beliefs.
Time frame: Baseline (week 0), week 4 and week 8
Change in DASS-21 Anxiety subscale score
7 items of the DASS-21 anxiety subscale, rated 0-3 (range 0-21). Higher scores indicate more anxiety symptoms.
Time frame: Baseline (week 0), week 4 and week 8
Reading adherence
Weekly one-item online reading log in the two bibliotherapy arms, recording the section of the book reached; summarized as the proportion of the book completed.
Time frame: Weekly, weeks 1-8
Contamination between study groups
Three-item form assessing access to the other group's book, sharing of book content between participants, and use of other psychological support during the study.
Time frame: Week 8
Plan to share: No — Individual participant data will not be shared outside the research team. This is in line with the ethics committee approval and the informed consent form, which state that data will be used only by the research team for the purposes of this study. Aggregate results will be published in a peer-reviewed journal.
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Jan 2027, 2 months after the start.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 2 months is below that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: start Jun 2026 → Oct 2026, primary completion Sep 2026 → Jan 2027 and completion Oct 2026 → Jan 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istanbul Nisantasi University